Ferulic acid-4-O-sulfate rather than ferulic acid relaxes arteries and lowers blood pressure in mice

Journal of Nutritional Biochemistry

Volumn 44, Issue , 2017, Pages 44-51

  Van Rymenant, Evelien ^a   Van Camp, John ^a   Pauwels, Bart ^b   Boydens, Charlotte ^b   Vanden Daele, Laura ^b   Beerens, Katrijn ^a   Brouckaert, Peter ^a   Smagghe, Guy ^a   Kerimi, Asimina ^c   Williamson, Gary ^c   Grootaert, Charlotte ^a   Van de Voorde, Johan ^b  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Blood pressure; Ferulic acid; Ferulic acid 4 O sulfate; Mouse; Vasorelaxation

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; AGLYCONE; FAMPRIDINE; FERULIC ACID; FERULIC ACID 4 O SULFATE; UNCLASSIFIED DRUG; VASODILATOR AGENT; COUMARIC ACID; FERULIC ACID-4-O-SULFATE; GUANYLATE CYCLASE; POLYPHENOL; POTASSIUM CHANNEL; SULFATE;

ANESTHESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD PRESSURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EX VIVO STUDY; FEMORAL ARTERY; FOOD DEPRIVATION; ISOLATED ARTERY; KNOCKOUT MOUSE; MALE; MEAN ARTERIAL PRESSURE; MOUSE; MYOGRAPHY; NONHUMAN; SAPHENOUS ARTERY; VASODILATATION; ANIMAL; ARTERY; CHEMISTRY; COFFEE; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; WHOLE GRAIN;

ANIMALS; ARTERIES; BLOOD PRESSURE; COFFEE; COUMARIC ACIDS; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, KNOCKOUT; POLYPHENOLS; POTASSIUM CHANNELS; SOLUBLE GUANYLYL CYCLASE; SULFURIC ACID ESTERS; VASODILATION; WHOLE GRAINS;

EID: 85016980959     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2017.02.018     Document Type: Article

References (47)

1. [1] Manach, C., Mazur, A., Scalbert, A., Polyphenols and prevention of cardiovascular diseases. Curr Opin Lipidol 16 (2005), 77–84.
2. [2] Middleton, E.J., Kandaswami, C., Theoharides, T.C., The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52 (2000), 673–751.
3. [3] D'Archivio, M., Filesi, C., Di Benedetto, R., Gargiulo, R., Giovannini, C., Masella, R., Polyphenols, dietary sources and bioavailability. Ann Ist Super Sanita 43 (2007), 348–361.
4. [4] El-Seedi, H.R., El-Said, A.M.A., Khalifa, S.A.M., Göransson, U., Bohlin, L., Borg-Karlson, A.K., et al. Biosynthesis, natural sources, dietary intake, pharmacokinetic properties, and biological activities of hydroxycinnamic acids. J Agric Food Chem 60 (2012), 10877–10895, 10.1021/jf301807g.
5. [5] Kroon, P.A., Faulds, C.B., Ryden, P., Robertson, J.A., Williamson, G., Release of covalently bound ferulic acid from fiber in the human colon. J Agric Food Chem 45 (1997), 661–667.
6. [6] Farrell, T.L., Gomez-juaristi, M., Poquet, L., Redeuil, K., Absorption of dimethoxycinnamic acid derivatives in vitro and pharmacokinetic profile in human plasma following coffee consumption. Mol Nutr Food Res 56 (2012), 1413–1423, 10.1002/mnfr.201200021.
7. [7] Higdon, J.V., Frei, B., Higdon, J.V., Frei, B., Coffee and health: a review of recent human research. Crit Rev Food Sci Nutr 46 (2016), 101–123, 10.1080/10408390500400009.
8. [8] Redeuil, K., Smarrito-menozzi, C., Guy, P., Rezzi, S., Dionisi, F., Williamson, G., et al. Identification of novel circulating coffee metabolites in human plasma by liquid chromatography–mass spectrometry. J Chromatogr A 1218 (2011), 4678–4688, 10.1016/j.chroma.2011.05.050.
9. [9] Bourne, L.C., Rice-Evans, C., Bioavailability of ferulic acid. Biochem Biophys Res Commun 253 (1998), 222–227, 10.1006/bbrc.1998.9681.
10. [10] Zhao, Z., Egashira, Y., Sanada, H., Digestion and absorption of ferulic acid sugar esters in rat gastrointestinal tract. J Agric Food Chem 51 (2003), 5534–5539.
11. [11] Erk, T., Williamson, G., Renouf, M., Marmet, C., Steiling, H., Dionisi, F., et al. Dose-dependent absorption of chlorogenic acids in the small intestine assessed by coffee consumption in ileostomists. Mol Nutr Food Res 56 (2012), 1488–1500, 10.1002/mnfr.201200222.
12. [12] Renouf, M., Marmet, C., Giuffrida, F., Barron, D., Beaumont, M., Williamson, G., et al. Dose–response plasma appearance of coffee chlorogenic and phenolic acids in adults. Mol Nutr Food Res 58 (2014), 301–309, 10.1002/mnfr.201300349.
13. [13] Virgili, F., Pagana, G., Bourne, L., Rimbach, G., Natella, F., Rice-Evans, C., et al. Ferulic acid excretion as a marker of consumption of a French maritime pine (Pinus maritima) bark extract. Free Radic Biol Med 28 (2000), 1249–1256, 10.1016/S0891-5849(00)00244-6.
14. [14] Silberberg, M., Morand, C., Mathevon, T., Besson, C., Manach, C., Scalbert, A., et al. The bioavailability of polyphenols is highly governed by the capacity of the intestine and of the liver to secrete conjugated metabolites. Eur J Nutr 45 (2006), 88–96, 10.1007/s00394-005-0568-5.
15. [15] Adam, A., Crespy, V., Levrat-Verny, M.-A., Leenhardt, F., Leuillet, M., Demigné, C., et al. The bioavailability of ferulic acid is governed primarily by the food matrix rather than its metabolism in intestine and liver in rats. J Nutr 132 (2002), 1962–1968.
16. [16] Lang, R., Dieminger, N., Beusch, A., Lee, Y., Dunkel, A., Suess, B., et al. Bioappearance and pharmacokinetics of bioactives upon coffee consumption. Anal Bioanal Chem 405 (2013), 8487–8503, 10.1007/s00216-013-7288-0.
17. [17] Stalmach, A., Mullen, W., Barron, D., Uchida, K., Yokota, T., Cavin, C., et al. Metabolite profiling of hydroxycinnamate derivatives in plasma and urine after the ingestion of coffee by humans: identification of biomarkers of coffee consumption. Drug Metab Dispos 37 (2009), 1749–1758, 10.1124/dmd.109.028019.contains.
18. [18] Alam, M.A., Subhan, N., Hossain, H., Hossain, M., Reza, H.M., Rahman, M.M., et al. Hydroxycinnamic acid derivatives: a potential class of natural compounds for the management of lipid metabolism and obesity. Nutr Metab (Lond), 13, 2016, 27, 10.1186/s12986-016-0080-3.
19. [19] Vinayagam, R., Jayachandran, M., Xu, B., Antidiabetic effects of simple phenolic acids: a comprehensive review. Phyther Res 30 (2015), 184–199, 10.1002/ptr.5528.
20. [20] Alam, M.A., Sernia, C., Brown, L., Ferulic acid improves cardiovascular and kidney structure and function in hypertensive rats. J Cardiovasc Pharmacol 61 (2013), 240–249, 10.1097/FJC.0b013e31827cb600.
21. [21] Choi, S., Il Kim, H., Hag Park, S., Jung Lee, M., Yeoul Jun, J., Lee Kim, H., et al. Endothelium-dependent vasodilation by ferulic acid in aorta from chronic renal hypertensive rats. Kidney Res Clin Pract 31 (2012), 227–233, 10.1016/j.krcp.2012.09.001.
22. [22] Suzuki, A., Yamamoto, M., Jokura, H., Fujii, A., Tokimitsu, I., Hase, T., et al. Ferulic acid restores endothelium-dependent vasodilation in aortas of spontaneously hypertensive rats. Am J Hypertens 20 (2007), 508–513, 10.1016/j.amjhyper.2006.11.008.
23. [23] Zhao, J., Suyama, A., Tanaka, M., Matsui, T., Ferulic acid enhances the vasorelaxant effect of epigallocatechin gallate in tumor necrosis factor-alpha-induced inflammatory rat aorta. J Nutr Biochem 25 (2014), 807–814, 10.1016/j.jnutbio.2014.03.013.
24. [24] Buys, E.S., Sips, P., Vermeersch, P., Raher, M.J., Rogge, E., Ichinose, F., et al. Gender-specific hypertension and responsiveness to nitric oxide in sGC a 1 knockout mice. Cardiovasc Res 79 (2008), 179–186, 10.1093/cvr/cvn068.
25. [25] Mulvany, M.J., Halpern, W., Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 41 (1977), 19–26.
26. [26] Chopra, S., Baby, C., Jacob, J.J., Neuro-endocrine regulation of blood pressure. Indian J Endocrinol Metab 15 (2011), S281–S288, 10.4103/2230-8210.86860.
27. [27] Kroon, P.A., Williamson, G., Hydroxycinnamates in plants and food: current and future perspectives. J Sci Food Agric 79 (1999), 355–361.
28. [28] Monagas, M., Urpi-Sarda, M., Sánchez-Patán, F., Llorach, R., Garrido, I., Gómez-Cordovés, C., et al. Insights into the metabolism and microbial biotransformation of dietary flavan-3-ols and the bioactivity of their metabolites. Food Funct 1 (2010), 233–253, 10.1039/c0fo00132e.
29. [29] Meisheri, K.D., Cipkus, L.A., Taylor, C.J., Mechanism of action of minoxidil sulfate-induced vasodilation: a role for increased K+ permeability. J Pharmacol Exp Ther 245 (1988), 751–760.
30. [30] Suzuki, A., Kagawa, D., Fujii, A., Ochiai, R., Tokimitsu, I., Saito, I., Short- and long-term effects of ferulic acid on blood pressure in spontaneously hypertensive rats. Am J Hypertens 15 (2002), 351–357, 10.1016/S0895-7061(01)02337-8.
31. [31] Chen, G.P., Ye, Y., Li, L., Yang, Y., Qian, A. Bin, Hu, S.J., Endothelium-independent vasorelaxant effect of sodium ferulate on rat thoracic aorta. Life Sci 84 (2009), 81–88, 10.1016/j.lfs.2008.11.003.
32. [32] Zhao, Y., Brandish, P.E., DiValentin, M., Schelvis, J.P.M., Babcock, G.T., Marletta, M.A., Inhibition of soluble guanylate cyclase by ODQ. Biochemistry 39 (2000), 10848–10854.
33. [33] Derbyshire, E.R., Marletta, M.A., Structure and regulation of soluble guanylate cyclase. Annu Rev Biochem, 81, 2012, 559, 10.1146/annurev-biochem-050410-100030.
34. [34] Hoffmann, L.S., Schmidt, P.M., Keim, Y., Hoffmann, C., Schmidt, H.H.H.W., Stasch, J.P., Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells. PLoS One, 6, 2011, 10.1371/journal.pone.0023596.
35. [35] Thoonen, R., Cauwels, A., Decaluwe, K., Geschka, S., Tainsh, R.E., Delanghe, J., et al. Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice. Nat Commun 6 (2015), 1–12, 10.1038/ncomms9482.
36. [36] Pyriochou, A., Papapetropoulos, A., Soluble guanylyl cyclase: more secrets revealed. Cell Signal 17 (2005), 407–413, 10.1016/j.cellsig.2004.09.008.
37. [37] Selwood, D.L., Brummell, D.G., Budworth, J., Burtin, G.E., Campbell, O., Chana, S.S., et al. Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase. J Med Chem 44 (2001), 78–93.
38. [38] Evgenov, O.V., Pacher, P., Schmidt, P.M., Haskó, G., Schmidt, H.H.H.W., Stasch, J.-P., NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5 (2006), 755–768, 10.1038/nrd2038.
39. [39] Priviero, F.B.M., Webb, R.C., Heme-dependent and independent soluble guanylate cyclase activators and vasodilation. J Cardiovasc Pharmacol 56 (2010), 229–233.
40. [40] Nelson, M.T., Quayle, J.M., Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol Cell Physiol 268 (1995), C799–C822.
41. [41] Sobey, C.G., Potassium channel function in vascular disease. Arterioscler Thromb Vasc Biol 21 (2001), 28–38.
42. [42] Kitazono, T., Ibayashi, S., Nagao, T., Fujii, K., Fujishima, M., Role of Ca2+-activated K+ channels in acetylcholine-induced dilatation of the basilar artery in vivo. Br J Pharmacol 120 (1997), 102–106.
43. [43] Wu, B., Chen, C., Hong, Y., Howng, S., Lin, Y., Chen, I., Activation of BK Ca channels via cyclic AMP- and cyclic GMP-dependent protein kinases by eugenosedin-A in rat basilar artery myocytes. Br J Pharmacol 152 (2007), 374–385, 10.1038/sj.bjp.0707406.
44. [44] Sobey, C.G., Faraci, F.M., Inhibitory effect of 4-aminopyridine on responses of the basilar artery to nitric oxide. Br J Pharmacol 126 (1999), 1437–1443.
45. [45] Irvine, J.C., Favaloro, J.L., Kemp-harper, B.K., NO− activates soluble guanylate cyclase and Kv channels to vasodilate resistance arteries. Hypertension 41 (2003), 1301–1307, 10.1161/01.HYP.0000072010.54901.DE.
46. [46] Schwab, A., Geibel, J., Wang, W., Oberleithner, H., Giebisch, G., Mechanism of activation of K+−channels by minoxidil sulfate in Main-Darby canine kidney cells. J Membr Biol 132 (1993), 125–136.
47. [47] Kauffman, F.C., Conjugation–deconjugation reactions in drug metabolism and toxicity. 1994.